Your browser doesn't support javascript.
loading
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Quinn, Zachary; Leiby, Benjamin; Sonpavde, Guru; Choudhury, Atish D; Sweeney, Christopher; Einstein, David; Szmulewitz, Russell; Sartor, Oliver; Knudsen, Karen; Yang, Eddy Shih-Hsin; Kelly, Wm Kevin.
Affiliation
  • Quinn Z; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania.
  • Leiby B; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania.
  • Sonpavde G; Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Choudhury AD; Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Sweeney C; Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Einstein D; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Szmulewitz R; University of Chicago, Chicago, Illinois.
  • Sartor O; Tulane University School of Medicine, Tulane Cancer Center, New Orleans, Louisiana.
  • Knudsen K; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania.
  • Yang ES; University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, Alabama.
  • Kelly WK; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania.
Clin Cancer Res ; 29(1): 50-59, 2023 01 04.
Article in En | MEDLINE | ID: mdl-36321991
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radium / Prostatic Neoplasms, Castration-Resistant / Neutropenia / Antineoplastic Agents Limits: Humans / Male Language: En Journal: Clin Cancer Res Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radium / Prostatic Neoplasms, Castration-Resistant / Neutropenia / Antineoplastic Agents Limits: Humans / Male Language: En Journal: Clin Cancer Res Year: 2023 Document type: Article